Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) has received a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $6.60.
A number of brokerages recently issued reports on ETTX. BMO Capital Markets decreased their target price on shares of Entasis Therapeutics from $15.00 to $5.00 and set an “outperform” rating on the stock in a research report on Friday, May 8th. CSFB reaffirmed an “outperform” rating and set a $8.00 price target on shares of Entasis Therapeutics in a research note on Sunday, June 21st. Zacks Investment Research downgraded shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 16th. HC Wainwright cut their price target on shares of Entasis Therapeutics from $18.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Finally, ValuEngine downgraded shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 18th.
In other Entasis Therapeutics news, major shareholder Innoviva, Inc. bought 12,677,490 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $2.50 per share, with a total value of $31,693,725.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 15.40% of the company’s stock.
NASDAQ ETTX traded up $0.07 during mid-day trading on Friday, reaching $2.94. 74,956 shares of the stock were exchanged, compared to its average volume of 143,396. Entasis Therapeutics has a 1-year low of $1.75 and a 1-year high of $9.25. The business’s fifty day simple moving average is $2.74 and its 200 day simple moving average is $3.83. The stock has a market capitalization of $41.94 million, a PE ratio of -0.84 and a beta of 2.09. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.67 and a current ratio of 5.67.
Entasis Therapeutics (NASDAQ:ETTX) last announced its earnings results on Thursday, May 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.00) by ($0.15). On average, analysts anticipate that Entasis Therapeutics will post -2.27 EPS for the current year.
About Entasis Therapeutics
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Featured Article: What is a Buy-Side Analyst?
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.